We study the molecular mechanisms underlying heart failure — from single-cell transcriptomics and cardiac epigenomics to iPSC models and population-scale prevention — bridging basic science with clinical impact across Southeast Asia.
Roger trained with the late Professor David de Bono (British Heart Foundation Chair of Cardiology, Leicester) before moving to Cambridge, where he worked under Professor Morris Brown MD, FRCP, FMedSci, FRS at the Clinical Pharmacology Unit.
Awarded a Wellcome Trust Fellowship, Roger joined Professor Rick Kitsis at Albert Einstein College of Medicine, NYC, exploring the molecular regulation of heart failure and cardiomyocyte apoptosis. He returned to Cambridge in 2006 to start Foo Lab 1.0 at the Division of Cardiovascular Medicine, funded by the British Heart Foundation and Wellcome Trust.
Foo Lab 2.0 was established in Singapore in 2013, expanding into genomics, transcriptomics, and population health. Roger holds several leadership roles at NUS, founded the NUHS Clinician Scientist Academy, and serves as chair of the MOH Clinician Scientist Residency Research Panel and President of the College of Clinician Scientists, Academy of Medicine Singapore.
"Our mission is to make impactful scientific discoveries through world-class research — and to train the next generation of scientists who will change how we understand the heart."
We use single-cell and spatial RNA sequencing to identify cardiomyocyte subpopulations, characterise circular and long non-coding RNAs, and develop AAV-based gene therapy strategies for heart failure.
Learn moreWe have mapped the global cardiac enhancer–promoter landscape and characterised genetic variants influencing disease risk through cis-regulatory activity — with a particular focus on Southeast Asian populations.
Learn moreUsing human embryonic and induced pluripotent stem cells, we model cardiac disease in vitro to probe cell-state transitions and test therapeutic interventions at single-cell resolution.
Learn moreCloser to the patient — we combine clinical samples, population health data, and CRISPR-based functional genomics to tackle the looming cardiometabolic crisis across Southeast Asia.
Learn moreProject RESET (Reducing Excess risk in Singapore through Enhanced Treatment) is a population-level clinical study aimed at preventing heart disease in Singapore. Working alongside primary care, community health, and national health bodies, we are identifying and intervening in high-risk individuals across Queenstown and beyond.
RESET brings together genomics, digital health, and community outreach in a concerted drive to reduce cardiovascular burden across Southeast Asia.
Our work spans high-impact journals in cardiovascular medicine, genomics, and precision health. Browse the full publication record via NUS Discovery or GitHub.